For people living with human immunodeficiency virus (HIV), life-saving antiretroviral therapy keeps their HIV-infected immune cells from making new copies of the virus, preventing illness and transmission.
A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and lenacapavir (BIC/LEN) – may simplify treatment significantly for people with HIV who currently take very complex treatments.
The World Health Organization (WHO) has certified Denmark for the elimination of mother-to-child transmission (EMTCT) of HIV and syphilis, recognizing the country's sustained commitment to ensuring every child is born free of these infections.
INCLIVA Healthcare Research Institute-University Clinical Hospital of Valencia, the Universitat Politècnica de València - through its VRAIN Institute, the Valencia Anti-AIDS Committee and the Centre for Epidemiological Studies on Sexually Transmitted Infections and AIDS in Catalonia (CEEISCAT) have joined forces to develop a spatial intelligence platform to support health policy decisions aimed at optimizing the prevention of human...
For people living with human immunodeficiency virus (HIV), life-saving antiretroviral therapy keeps their HIV-infected immune cells from making new copies of the virus, preventing illness and transmission.
Over two decades, medical care improvements increased health spans in the U.S. by 1.3 years and medical spending by $234,000 per person over their lifetime – or about $182,000 per additional healthy year of life gained – when measured from birth. These are among the key findings in a new in-depth national study published today in Value in Health.
What impact does a viral infection have on our memory, attention, and concentration? The COVID-19 pandemic has reignited interest in this question, which has now been extended to other infections such as HIV, herpes, and hepatitis.
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of
our websites
and requested to be notified of additional information.
